Artelo Biosciences (ARTL) Depreciation & Amortization - Total (2017 - 2018)
Artelo Biosciences (ARTL) posted quarterly Depreciation & Amortization - Total of $71.0 for Q3 2018, down 2.74% quarter-over-quarter from $73.0 in Q2 2018.
Artelo Biosciences (ARTL) Depreciation & Amortization - Total (2017 - 2018) Analysis & Trends
Artelo Biosciences (ARTL) has reported Depreciation & Amortization - Total for 2 consecutive years, with $71.0 the latest figure, recorded in Q3 2018.
- In Q3 2018, Depreciation & Amortization - Total changed N/A year-over-year to $71.0; the TTM figure through May 2019 stood at $71.0 (down 67.58% YoY), while the FY2020 annual figure was $500.0, down 1.96% from the prior year.
- Depreciation & Amortization - Total declined to $71.0 in Q3 2018 per ARTL's latest filing, from $73.0 in the prior quarter.
- Across five years, Depreciation & Amortization - Total topped out at $74.0 in Q1 2018 and bottomed at $71.0 in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Tot) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Artelo Biosciences | 107,735.40 | -492,264.60 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Aug 31, 2018 | 71.00 |
| May 31, 2018 | 73.00 |
| Feb 28, 2018 | 74.00 |
| Nov 30, 2017 | 72.00 |